PCSK9 and familial hyperaldosteronism: The first study exploring the effects of inclisiran on both lipid profiles and pulse wave velocity in FH subjects demonstrated that non-HDL cholesterol as well as PWV could be improved using statins, ezetimibe or PCSK9 inhibitors.